On July 16, JD Health rose 3.68% in regular trading, trading at HKD 38.5 per share, with turnover of HKD 55.48 million. The gain was driven by the announcement of a strategic partnership with biopharmaceutical company Everest Medicines.

On July 15, JD Health and Everest Medicines signed a strategic cooperation agreement. The two parties will collaborate on innovative drug new product launches, patient services, digital marketing, and internet healthcare. Under the agreement, Everest Medicines will prioritize launching new products on the JD Health platform, leveraging first-tier direct supply, omni-channel supply chain coordination, and digital academic marketing to improve drug accessibility and service quality. Everest Medicines' oral innovative drugs, including Nefecon and Filsuvez, are already available on the JD Health platform.

Within the Internet and Direct Marketing Retail sector, the broader sector showed strength. Among individual stocks, BABA-W up 3.79%, MEITUAN-W up 3.78%, ALI HEALTH up 2.98%, PA GOODDOCTOR up 2.82%, JD-SW up 2.16%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)